← Back to Home

First-in-human trial of trispecific CAR T cells: rapid on-site manufacturing and remissions in lymphoma patients

Can recognizing three cancer cell markers at once reduce tumor escape and shorten patients’ wait? A small Ohio State University trial offers early clues, but manufacturing feasibility and early responses are still a long way from durable efficacy.

By SURL BioNews

For patients with relapsed or treatment-resistant B-cell blood cancers, treatment must overcome two hurdles: enabling immune cells to recognize cancer cells and delivering the therapy back to patients in time. An Ohio State University team has reported results from a first-in-human trial combining trispecific CAR T cells with rapid on-site manufacturing. Remissions observed in some lymphoma patients offer preliminary clinical clues addressing both challenges.

CAR T therapy involves collecting a patient’s T cells, genetically modifying them, and infusing them back into the body so they can recognize specific cancer cell markers. This study targets CD19, CD20, and CD22 simultaneously, with a design intended to reduce the chance that cancer cells evade recognition after losing a single marker. The receptor also incorporates an OX40 costimulatory domain in the hope of strengthening the T cells’ immune response. Whether these designs can improve long-term treatment outcomes requires further testing with human data.

The study was published in *Blood Cancer Discovery* on September 3, and the university presented the findings on October 13. The trial enrolled 18 people, of whom 16 received infusions at doses ranging from 500,000 to 2 million cells per kilogram of body weight. The paper’s abstract reported an overall response rate of 50% and a complete response rate of 83% among lymphoma patients. These two figures cover different patient populations, so the higher percentage cannot be applied to all participants. The university said remissions occurred in types including mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma.

The manufacturing timeline was also a focus of the trial. The university’s news release described the rapid process as taking six days, while the study methods listed six days as the target from collection to infusion. The published paper’s abstract reported that the actual median “collection-to-infusion” time was seven days. Six days therefore cannot be interpreted as a timeline achieved for every patient. The cells were prepared in an on-site laboratory, demonstrating the feasibility of local manufacturing, but whether the process can be consistently reproduced at more hospitals remains to be verified.

Regarding safety, none of the 16 treated participants developed severe cytokine release syndrome or neurotoxicity; overall one-year survival was 61%. These results provide preliminary signals of safety and efficacy, but they are insufficient to rule out less common adverse reactions or demonstrate that the therapy is superior to existing options. A complete response means no detectable disease was found at the time of assessment; it does not mean the patient has been cured.

The study also found that features of T-cell exhaustion in the collected cells were associated with disease progression, suggesting that efficacy may also be influenced by the initial state of a patient’s cells. This association remains an exploratory finding and cannot yet be used to determine who is suitable for treatment. According to the university’s 2023 introduction to the trial, the study received support from the U.S. National Cancer Institute and the Pelotonia Idea Grant Program, while Miltenyi Biotec supplied the gene vector needed for manufacturing. The phase 1 trial’s objectives include assessing manufacturing feasibility and safety and identifying a recommended dose for a planned phase 2 study.

This trial brings multi-target recognition and rapid manufacturing into clinical practice, but its small number of participants and inclusion of different B-cell malignancies still make it difficult to determine which patients are most likely to benefit. Larger studies with longer follow-up are needed next to clarify how long remissions last and how much benefit the trispecific and OX40 designs each contribute. For patients, both shorter waits and longer disease control must ultimately withstand clinical validation.

References

  1. Medical Xpress / Ohio State University Medical Center
  2. Blood Cancer Discovery / PubMed
  3. Ohio State University Comprehensive Cancer Center – James